Nano-crystalline megestrol acetate
Phase 3Small molecule
Changchun GeneScience Pharmaceutical Co., Ltd.Nano-crystalline megestrol acetate is one of 211 small molecule programs targeting Cachexia. It is currently in Phase 3.
7
Indications
8
Total Trials
8
Active Trials
210
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-crystalline megestrol acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
Imjudo
AstraZenecaPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cachexia2 trials
Head and Neck Squamous Cell Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]
- [4]
Details